Can ARKK rebound from its steep decline, or just mirror market trends? Read our insight on its potential to deliver alpha ...

JEPQ aims to generate income by selling NASDAQ 100 call options but fails to smooth volatility or outperform in bull markets.

Eledon Pharmaceuticals is poised to revolutionize kidney transplant care with tegoprubart, targeting a $6B market. Read why ...

Prudential Financial is positioned for 54% returns by 2027, with solid liquidity and mid-single-digit dividend growth. Read ...

Blue Bird Corporation is undervalued, with strong financials and growth potential, making it a compelling buy at a 8.8x PE.

Get a timely nowcast of the economy with high-frequency indicators. Click for how short leading indicators showed improvement ...

Prudential Financial is bouncing back with strong earnings, a solid balance sheet, and undervalued shares. Find out why PRU ...

Ingersoll Rand’s buying spree boosted revenue but hurt margins and ballooned debt, raising concerns for investors. Read why ...

MetLife leverages diversification and acquisitions to drive earnings and resilience amid economic shifts. Find out why MET ...

ITOCHU balances commodity weakness with strong non-resource growth and resilient earnings, justifying its premium. Learn why ...

Evolve Canadian Utilities Enhanced Yield Index Fund ETF struggles with market volatility despite high yields and assess its ...

AGCO Corporation saw 30% sales drop. Read here to know why AGCO stock's investors reacted positively, and why this analyst is ...